Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.77 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7224530 | 0.92 | LTC4S (0.87) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL6847403 | 0.88 | LTC4S (1.00) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL5888407 | 0.87 | LTC4S (0.79) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL5888522 | 0.87 | LTC4S (0.79) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL7624466 | 0.87 | ALDH1A1 (1.00) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL29355043 | 0.87 | ALDH1A1 (1.00) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL6231736 | 0.86 | LTC4S (0.74) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL29352042 | 0.82 | ALDH1A1 (1.00) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL13996738 | 0.80 | ALDH1A1 (0.77) | LTC4SALDH1A1RAB9ALMNAKMT2A | |
| SCHEMBL13885949 | 0.79 | ALDH1A1 (0.68) | LTC4SALDH1A1RAB9ALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586450-B2 | E.g., (2-(4-methoxyphenethyl))-N'-(2-(5-bromopyridyl))-thiourea; enzyme inhibitors of reverse transcriptase; viricides for HIV infection, including mutant, drug-sensitive, drug and multi-drug resistance strains | PARKER HUGHES INSTITUTE | 2003-07-01 | — | — | US | claimed |
| EP-1194406-A1 | PHENETYL-THIOUREA COMPOUNDS FOR TREATING HIV INFECTIONS | Parker Hughes Institute (US) | 2002-04-10 | — | — | EP | claimed |
| US-20020028837-A1 | Phenethyl-thiourea compounds and use | WAYNE HUGHES INSTITUTE | 2002-03-07 | — | — | US | claimed |
| US-20010039276-A1 | Phenethyl-thiourea compounds and use | PARKER HUGHES INSTITUTE (US) | 2001-11-08 | — | — | US | claimed |
| US-20010003748-A1 | Phenethyl-thiourea compounds and use | PARKER HUGHES INSTITUTE (US) | 2001-06-14 | — | — | US | claimed |
| US-6207688-B1 | TREATING MULTI-DRUG RESISTANT, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE RESISTANT, AND THERAPY NAIVE HIV INFECTION BY ADMINISTERING PHENETHYL-THIOUREA DERIVATIVE | PARKER HUGHES INSTITUTE | 2001-03-27 | — | — | US | claimed |
| WO-2000078721-A1 | PHENETYL-THIOUREA COMPOUNDS FOR TREATING HIV INFECTIONS | PARKER HUGHES INSTITUTE (US) | 2000-12-28 | — | — | WO | claimed |
| US-6586450-B2 | E.g., (2-(4-methoxyphenethyl))-N'-(2-(5-bromopyridyl))-thiourea; enzyme inhibitors of reverse transcriptase; viricides for HIV infection, including mutant, drug-sensitive, drug and multi-drug resistance strains | PARKER HUGHES INSTITUTE | 2003-07-01 | — | — | US | disclosed |
| US-6407246-B2 | REVERSE TRANSCRIPTASE INHIBITORS TO TREAT HIV | PARKER HUGHES INSTITUTE | 2002-06-18 | — | — | US | disclosed |
| EP-1194406-A1 | PHENETYL-THIOUREA COMPOUNDS FOR TREATING HIV INFECTIONS | Parker Hughes Institute (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6362228-B2 | CYCLOALKY OR HETEROCYCLIC SUBSTITUTED PHENETHYL-THIOUREA COMPOUNDS USED AS INHIBITOR OF REVERSE TRANSCRIPTASE AND EFFECTIVE AGENTS FOR HIV INFECTION TREATMENT, INCLUDING MUTANT, DRUG SENSITIVE OR DRUG RESISTANT STRAINS OF HIV | PARKER HUGHES INSTITUTE | 2002-03-26 | — | — | US | disclosed |
| US-20020028837-A1 | Phenethyl-thiourea compounds and use | WAYNE HUGHES INSTITUTE | 2002-03-07 | — | — | US | disclosed |
| US-20010039276-A1 | Phenethyl-thiourea compounds and use | PARKER HUGHES INSTITUTE (US) | 2001-11-08 | — | — | US | disclosed |
| US-20010003748-A1 | Phenethyl-thiourea compounds and use | PARKER HUGHES INSTITUTE (US) | 2001-06-14 | — | — | US | disclosed |
| US-6207688-B1 | TREATING MULTI-DRUG RESISTANT, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE RESISTANT, AND THERAPY NAIVE HIV INFECTION BY ADMINISTERING PHENETHYL-THIOUREA DERIVATIVE | PARKER HUGHES INSTITUTE | 2001-03-27 | — | — | US | disclosed |
| WO-2000078721-A1 | PHENETYL-THIOUREA COMPOUNDS FOR TREATING HIV INFECTIONS | PARKER HUGHES INSTITUTE (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028837-A1 | Phenethyl-thiourea compounds and use | TPMT, PNMT, PNP | LTC4S 3270/4885ALDH1A1 2901/4885RAB9A 2074/4885 |
| US-20010039276-A1 | Phenethyl-thiourea compounds and use | TPMT, PNMT, PNP | LTC4S 3270/4885ALDH1A1 2901/4885RAB9A 2074/4885 |
| US-20010003748-A1 | Phenethyl-thiourea compounds and use | TPMT, PNMT, PNP | LTC4S 3270/4885ALDH1A1 2901/4885RAB9A 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.